PAX6 and Huntington disease: This pioneering study demonstrated that molecules AN1 and AN2 (Figure 7B) effectively degrade mHTT in both cellular and in vivo animal models, successfully rescuing phenotypes associated with Huntington’s disease (Li et al., 2019).